Efficacy and Safety of Adalimumab in Inflammatory Bowel Disease

Efficacy in Crohn's Disease

Adalimumab is effective for induction of clinical remission in moderate-to-severe Crohn's disease with a relative risk of 3.58 (95% CI: 2.42–5.29) compared to placebo within 4 weeks of therapy initiation 1, 2
For maintenance therapy, adalimumab demonstrates efficacy over placebo with a relative risk of 2.70 (95% CI: 1.75–4.19) for maintaining clinical remission at 52-56 weeks 1, 2
Endoscopic outcomes show significant improvement with adalimumab compared to placebo, including endoscopic remission, endoscopic response, and mucosal healing 2

In ulcerative colitis, adalimumab shows more modest efficacy compared to Crohn's disease, with remission rates of 19% at week 8 in the ULTRA1 trial and 21% at week 8 in the ULTRA2 trial 4, 3
The American Gastroenterological Association guidelines suggest using infliximab or vedolizumab rather than adalimumab for induction of remission in moderate-severe ulcerative colitis (conditional recommendation, moderate quality evidence) 5, 6
Vedolizumab demonstrated superior clinical remission rates compared to adalimumab (34.2% vs. 24.3%) in biologic-naïve ulcerative colitis patients 7, 6

The safety profile of adalimumab is generally favorable, with no significant difference in adverse events between adalimumab and placebo during induction (RR: 0.91; 95% CI: 0.75-1.11) 1, 2
The combination of anti-TNF therapy with thiopurines is associated with increased risk of serious infections and malignancies, though absolute rates remain very low 1, 2

Standard induction dosing for adalimumab in Crohn's disease and ulcerative colitis is 160 mg at week 0, 80 mg at week 2, followed by 40 mg every other week 4, 1, 3
Adalimumab is not recommended for acute severe ulcerative colitis, as there are insufficient data supporting its use in this setting 8, 9

Response to adalimumab therapy should be evaluated at 8-12 weeks to determine the need for treatment modification 10
Quality of life improvements are observed within 4 weeks of therapy initiation based on IBDQ scores 1, 2
Therapeutic drug monitoring may be useful to optimize dosing, though specific target levels are still being established 5